Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Discs large MAGUK scaffold protein 5 (DLG5) is a member of the membrane-associated guanylate kinase (MAGUK) protein family, functioning predominantly as a molecular scaffold at cell-cell contact sites[1][3][5]. DLG5 contains PDZ, SH3, GUK, coiled-coil, and CARD domains, allowing it to interact with a wide variety of proteins—most notably components of adherens junctions (such as β-catenin and N-cadherin), the cytoskeleton, polarity complexes, and signaling receptors[1][2]. It is highly conserved in animals and localizes to the plasma membrane and adherens junctions, where it orchestrates the assembly and stabilization of protein complexes essential for epithelial polarity and tissue architecture[1][3][5][6]. In development and cancer, DLG5 regulates several essential processes, including cell proliferation, migration, and differentiation, mainly through modulation of the Hippo signaling pathway and by maintaining junctional integrity[1][2][4][5]. It acts as a negative regulator of Hippo signaling by scaffolding and inhibiting key kinases (e.g., MST1/2), influencing downstream transcription important for organ size and growth[1]. DLG5 also participates in the Sonic Hedgehog (Shh) pathway in certain tumor contexts, such as glioblastoma, where it promotes tumor cell viability and migration through stabilization of Shh pathway effectors[4]. Genetic mutations or dysregulation of DLG5 have been associated with multiple diseases, ranging from epithelial morphogenesis defects, inflammatory bowel diseases (e.g., Crohn’s disease), to various cancers[2][3][4]. Despite its involvement in cellular signaling pathways, DLG5 is not currently recognized as a direct therapeutic drug target (such as a receptor, enzyme, transporter), and there are no known approved drugs that specifically target DLG5[3][4]. Overall, DLG5 is primarily considered a scaffold/adaptor protein crucial for epithelial cell polarity and tissue organization, indirectly influencing signaling pathways and disease mechanisms rather than serving as a conventional drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Discs large MAGUK scaffold protein 5 (DLG5).